Skip to main content
Northwestern University Feinberg School of Medicine
The Ken & Ruth Davee Department of Neurology
Skip to main content

Neuromuscular Disease Trials

As part of an academic medical center, the Division of Neuromuscular Disease at Northwestern University Feinberg School of Medicine aims to improve human health through scientific research. Clinical trials test or study drugs, surgical procedures, medical devices or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.

The following searchable list includes all the neuromuscular disease clinical trials currently looking for participants.

Trials
Peripheral Neuropathy Research Registry (PNRR)
National Peripheral Neuropathy Research Registry, a collection of different types of information, such as patient medical, family, and social histories and blood samples. The information is carefully maintained so that it can be studied repeatedly in t…
National Peripheral Neuropathy Research Registry, a collection of different types of information, such as patient medical, family, and social histories and blood samples. The information is carefully maintained so that it can be studied repeatedly in the future. The registry aims to help researchers’ access large amounts of information about people with PN. By using this registry, researchers will facilitate both basic and clinical research studies that will bring improved understandings of the etiology (origination) and pathogenesis (development) of PN. They will specifically ask why some patients with peripheral neuropathy develop neuropathic pain and others do not, and what the characteristics of patients with painful peripheral neuropathy are in terms of their symptoms, examination findings, and blood tests. Ultimately this research may result in improved diagnosis, more effective treatments, and possibly prevention.
Inclusion criteria: 1. Diabetic Peripheral Neuropathy 2. Chemo-therapy Induced Peripheral Neuropathy 3. HIV-induced Peripheral Neuropathy 4. Idiopathic Peripheral Neuropathy; Exclusion criteria: Any other type of Peripheral Neuropathy
Ajroud-Driss, SendaAjroud-Driss, Senda
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00048864
More Info

For more information on this study please contact us:

Joslin, Benjamin 312 503 7504
Copy
cIRB: Topiramate as a disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)
This is a 96-week placebo-controlled trial of topiramate at a target dose of 100 mg daily (50 mg twice daily) as a potentially disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy
INCLUSION: 1. Age 18-75; 2. Diagnosis of confirmed cryptogenic symptomatic distal symmetric peripheral polyneuropathy; 3. Prediabetes based on American Diabetes Association; 4. No history of prior therapy with topiramate; 5. Waist circumference >102 cm for men, >88 cm for women
Menichella, DanielaMenichella, Daniela
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT02878798 STU00206049
More Info

For more information on this study please contact us:

Houseman, Justine +1 312 695 2296
Copy
Radicava® (Edaravone) Biomarker Study in Participants with Amyotrophic Lateral Sclerosis
REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and p…
REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.

Location of study: Les Turner ALS Center at Northwestern Medicine, 259 E. Erie St., Lavin 19, Chicago, IL 60611.

Ajroud-Driss, SendaAjroud-Driss, Senda
NCT04259255 STU00210057
More Info

For more information on this study please contact us:

Joslin, Benjamin 000 000 0000
Copy
Natural history study of ALS and other motor neuron disorders

Location of study: Les Turner ALS Center at Northwestern Medicine, 259 E. Erie St., Lavin 19, Chicago, IL 60611.

Ajroud-Driss, SendaAjroud-Driss, Senda
STU00209860
More Info

For more information on this study please contact us:

Joslin, Benjamin 000 000 0000
Copy
Oxidative Markers and Efficacy in ALS/MND Phenotypes Treated with Edaravone

We are only recruiting patients who have not started their edaravone treatment.

Location of study: Les Turner ALS Center at Northwestern Medicine, 259 E. Erie St., Lavin 19, Chicago, IL 60611.

Inclusion:

Either possible, probable, or definite ALS,predominantly lower motor neuron disease Predominantly upper motor neuron disease, orbulbar

With or without cognitive involvement

Willing to participate

On no experimental treatment

Ages 18 - 85

No prior exposure to Radicava

On a stable dose of riluzole for 30 days or offriluzole

Male or female

Females of childbearing age must usecontraception

Exclusion:

Unstable medical illness

Abnormal liver function (>2x ULN)

Unlikely to survive for at least 26 weeks

Ajroud-Driss, SendaAjroud-Driss, Senda
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT04097158 STU00211350
More Info

For more information on this study please contact us:

Joslin, Benjamin 312 503 7504
Copy
Platform Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

In this trial, multiple investigational products for ALS will be tested simul…

In this trial, multiple investigational products for ALS will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. Each regimen consists of a placebo-controlled trial, meaning that the active investigational product and matching placebo will be tested in each regimen.

The additional details that govern the testing of each investigational product will be summarized in separate regimen-specific appendices (RSAs). Each regimen will have a separate ClinicalTrials.gov posting, which will include specific information about the regimen. All regimen-specific outcome measures will be detailed in each regimen posting.

Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized in a 3:1 ratio to either study drug or placebo.

The following regimens are active in the trial:

Regimen A - Zilucoplan Regimen B - Verdiperstat Regimen C - CNM-Au8

New regimens will be continuously added as new investigational products become available. The HEALEY ALS Platform Trial will enroll additional participants as each new regimen is available.

Location of study: Les Turner ALS Center at Northwestern Medicine, 259 E. Erie St., Lavin 19, Chicago, IL 60611.

Ajroud-Driss, SendaAjroud-Driss, Senda
NCT04297683 STU00212680
More Info
ALS Platform

For more information on this study please contact us:

Joslin, Benjamin 000 000 0000
Copy
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation
This is a randomized, double-blind, placebo-controlled, 3-part dose escalation stud…
This is a randomized, double-blind, placebo-controlled, 3-part dose escalation study to examine the efficacy, safety, tolerability of BIIB067, administered by intrathecal bolus injection to up to approximately 183 adult subjects with ALS and confirmed SOD1 mutation.Northwestern is only participating in Part C of this study.The primary objective of Part C of this study is to evaluate the clinical efficacy of BIIB067 administered to adult subjects with ALS, who are fast-progressing, and confirmed SOD1 mutation.

Location of study: Les Turner ALS Center at Northwestern Medicine, 259 E. Erie St., Lavin 19, Chicago, IL 60611.

Ajroud-Driss, SendaAjroud-Driss, Senda
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT02623699 STU00211658
More Info
ALS SOD1

For more information on this study please contact us:

Joslin, Benjamin 000 000 0000
Copy
Back to top